Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

BACKGROUND: With the revolutionary progress of immune checkpoint inhibitors (ICIs) achieved in non-small cell lung cancers (NSCLC), identifying patients benefiting from ICIs becomes critical and urgent. The associations of genomic alterations in protein tyrosine phosphatase receptor-type (PTPRs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yiting, Duan, Jianchun, Fang, Wenfeng, Wang, Zhijie, Du, Xinyang, Wang, Xin, Li, Chengcheng, Cai, Shangli, Zhao, Jie, Li, Sini, Zhang, Li, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496052/
https://www.ncbi.nlm.nih.gov/pubmed/34615542
http://dx.doi.org/10.1186/s12916-021-02075-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496052/
https://www.ncbi.nlm.nih.gov/pubmed/34615542
http://dx.doi.org/10.1186/s12916-021-02075-5

Ejemplares similares